By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead Sciences is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Pigot most recently served as chief commercial officer at Aerovate Therapeutics, which was developing a dry powder inhaled ...

For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...